WX390
1 product
1 abstract
2 targets
Target
PI3KδTarget
mTORAbstract
Phase Ib study of a high potent PI3K-mTOR dual inhibitor WX390 combined with toripalimab in patients with advanced solid tumors.Org: Department of Gynecologic Oncology, Gynecology and Obstetrics Center, The First Hospital of Jilin University, Changchun, China, Phase I Clinical Research Center, The First Hospital of Jilin University, Changchun, China, The First Hospital of Jilin University, Changchun, Jilin Province, China, Shanghai Jiatan Pharmatech CO., LTD., Shanghai, Shanghai, China, Shanghai Jiatan Pharmatech CO., LTD., Shanghai, China,
Product
WX390 + Toripalimab